Ignite Creation Date:
2024-05-06 @ 4:22 PM
Last Modification Date:
2024-10-26 @ 2:09 PM
Study NCT ID:
NCT04964934
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-06-04
First Post:
2021-06-30
Brief Title:
Phase III Study to Assess AZD9833 CDK46 Inhibitor in HRHER2-MBC With Detectable ESR1m Before Progression SERENA-6
Sponsor:
AstraZeneca
Organization:
AstraZeneca
Conditions & Keywords Data
Conditions:
| Name |
|---|
| ER-Positive HER2-Negative Breast Cancer |
Keywords:
| Name | View |
|---|---|
| Endocrine Resistance | View |
| Metastatic | View |
| Breast Neoplasms | View |
| Neoplasms by Site | View |
| Neoplasms | View |
| Breast Diseases | View |
| Physiological Effects of Drugs | View |
| Randomised | View |
| Multicentre | View |
| Double-Blind | View |
| Phase III | View |
| AZD9833 | View |
| Next Generation Oral SERD | View |
| Anastrozole | View |
| Letrozole | View |
| Palbociclib | View |
| Abemaciclib | View |
| Ribociclib | View |
| Antagonists | View |
| Antineoplastic Agents | View |
| Estrogen Receptor Antagonists | View |
| Hormone Antagonists | View |
| camizestrant | View |
| ESR1m | View |
| Switch Treatment | View |
| Endocrine Therapy | View |